内脏转移对去势抵抗性前列腺癌患者多西他赛后阿比特龙治疗结局的影响。
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
作者信息
Conteduca Vincenza, Caffo Orazio, Fratino Lucia, Lo Re Giovanni, Basso Umberto, D'Angelo Alessandro, Donini Maddalena, Verderame Francesco, Ratta Raffaele, Procopio Giuseppe, Campadelli Enrico, Massari Francesco, Gasparro Donatello, Ermacora Paola, Messina Caterina, Giordano Monica, Alesini Daniele, Zagonel Vittorina, Veccia Antonello, Lolli Cristian, Maines Francesca, De Giorgi Ugo
机构信息
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Santa Chiara Hospital, Trento, Italy.
出版信息
Future Oncol. 2015;11(21):2881-91. doi: 10.2217/fon.15.158. Epub 2015 Oct 5.
BACKGROUND
The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone.
MATERIALS & METHODS: All CRPC patients received abiraterone 1000 mg daily plus prednisone 10 mg orally daily. Liver and lung metastases were considered as visceral metastases.
RESULTS
Of 265 CRPC patients, 49 had visceral metastases. Results on progression-free survival were not significantly different in patients with or without visceral metastases. Conversely, the median overall survival between the two groups was 12.4 and 18.5 months (p = 0.01), respectively, and median overall survival of patients with liver-only disease versus other sites was 10.5 versus 18.5 months (p = 0.006), respectively.
CONCLUSION
Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone.
背景
本研究的目的是分析阿比特龙治疗去势抵抗性前列腺癌（CRPC）时内脏转移的影响。
材料与方法
所有CRPC患者接受每日1000毫克阿比特龙加每日口服10毫克泼尼松治疗。肝转移和肺转移被视为内脏转移。
结果
265例CRPC患者中，49例有内脏转移。有无内脏转移患者的无进展生存期结果无显著差异。相反，两组的中位总生存期分别为12.4个月和18.5个月（p = 0.01），单纯肝转移患者与其他部位转移患者的中位总生存期分别为10.5个月和18.5个月（p = 0.006）。
结论
内脏疾病似乎是阿比特龙治疗CRPC患者临床结局的重要预测指标。
Zotero 插件